Here’s what’s behind the ads accusing Bob Hugin of ‘killing off cancer patients’
From the article:
"They're resorting to tactics the FDA criticized. Under the guise of patient safety, this is really about preserving a monopoly position," said law professor Rachel Sachs, who teaches at Washington University in St. Louis, Missouri.
"Companies with monopoly positions have the ability to raise prices year after year, quarter after quarter, even, with impunity, and Medicare is required to pay — even some private insurers are required to pay," Sachs said. "They're raising prices not necessarily because they've given something new to society, but because they can."
Read the full article.health care finance health law policy insurance medicaremedicaid pharmaceuticals rachel sachs regulation